Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Ascendis Health's Debt-to-Equity or its related term are showing as below:
JSE:ASC's Debt-to-Equity is not ranked *
in the Medical Distribution industry.
Industry Median: 0.48 * Ranked among companies with meaningful Debt-to-Equity only.
Ascendis Health (JSE:ASC) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Ascendis Health Debt-to-Equity Related Terms
Ascendis Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Ascendis Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:ASC vs PHBI, GCAN, SGBI: Debt-to-Equity Comparison
For the Medical Distribution subindustry, Ascendis Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Health Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ascendis Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Ascendis Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Health (JSE:ASC) has a Debt-to-Equity of 0.09 as of Jun. 2023. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ascendis Health and its competitors.
Is Ascendis Health's Debt-to-Equity too high?
Ascendis Health's current Debt-to-Equity is 0.09. The Medical Distribution industry median Debt-to-Equity is 0.48. Ascendis Health's value of 0.09 is 81.3% below this industry median. Overall, Ascendis Health has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Health's Debt-to-Equity compare to PHBI and GCAN?
Ascendis Health's Debt-to-Equity of 0.09 can be compared against companies in the Medical Distribution industry. The industry median Debt-to-Equity is 0.48. Ascendis Health's value of 0.09 is 81.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Health's current Debt-to-Equity of 0.09 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ascendis Health and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Health's current Debt-to-Equity is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Health stock overvalued right now?
Ascendis Health (JSE:ASC) has a current Debt-to-Equity of 0.09. The current Debt-to-Equity is 0.09 and 81.3% below the Medical Distribution industry median of 0.48. Ascendis Health's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ascendis Health (JSE:ASC), the current Debt-to-Equity is 0.09 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Health Ltd is a health and wellness investment holding Company that holds investments in a number of companies that market and distribute a portfolio of brands, products, and medical devices. The company operates in two segments: i) Consumer Health (wellness, health supplements, speciality ingredients and compounded medicines) and ii) Medical Devices (distributor of medical devices, in vitro diagnostic products and orthopaedic equipment). The company generates the majority of its revenue from the Medical Devices segment.
11GF Score
Get the complete analysis for JSE:ASC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:ASC has been successfully added to your 
